Gastric cancer: genes and variants
Explore variant evidence for Gastric cancer across 21 analyzed proteins (MUTYH, FGFR2, ERBB2, EPCAM, PIK3CA and 16 more). Linked ClinVar records include 19 pathogenic or likely pathogenic variants, 88 variants of uncertain significance and 51 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Gastric cancer
MUTYH: Adenine DNA glycosylase
It removes adenines incorrectly paired with oxidized guanine, preventing characteristic G:C-to-T:A mutations during base-excision repair. Biallelic loss-of-function variants cause MUTYH-associated polyposis and substantially increase colorectal-cancer risk.
11 ClinVar pathogenic / likely pathogenic and 75 uncertain variants in MUTYH have source records linked to Gastric cancer. Association strength is not clinical gene validity.
FGFR2: Fibroblast growth factor receptor 2
Its fibroblast-growth-factor signaling regulates proliferation, differentiation, and developmental patterning across multiple tissues. Germline activating variants cause several craniosynostosis syndromes, while somatic mutations, amplification, or fusions can drive cancer.
2 ClinVar pathogenic / likely pathogenic and 5 uncertain variants in FGFR2 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
ERBB2: Receptor tyrosine-protein kinase erbB-2
ERBB2, also called HER2, is a cell-surface receptor tyrosine kinase that works with other ERBB receptors to transmit growth signals. It helps organize signaling and cytoskeletal responses, and abnormal ERBB2 activity is a major feature of several cancers.
1 ClinVar pathogenic / likely pathogenic and 34 uncertain variants in ERBB2 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
EPCAM: Epithelial cell adhesion molecule
It supports epithelial organization and signaling at cell-cell interfaces. Deletions extending through its 3-prime end can silence neighboring MSH2 and cause Lynch syndrome, while biallelic loss-of-function variants cause congenital tufting enteropathy.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in EPCAM have source records linked to Gastric cancer. Association strength is not clinical gene validity.
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in PIK3CA have source records linked to Gastric cancer. Association strength is not clinical gene validity.
PALB2: Partner and localizer of BRCA2
It physically links BRCA1 and BRCA2 and helps recruit BRCA2-RAD51 repair machinery to DNA double-strand breaks. Heterozygous loss-of-function variants substantially increase breast and pancreatic cancer risk, while biallelic variants cause Fanconi anemia subtype N.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PALB2 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TP53 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
APC: Adenomatous polyposis coli protein
A tumor-suppressor protein that promotes the removal of beta-catenin and helps keep Wnt signaling under control. It also organizes microtubules and actin in the cell, and inherited APC disruption is strongly associated with familial adenomatous polyposis and colorectal tumor risk.
0 ClinVar pathogenic / likely pathogenic and 20 uncertain variants in APC have source records linked to Gastric cancer. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
0 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in KRAS have source records linked to Gastric cancer. Association strength is not clinical gene validity.
RAD51D: DNA repair protein RAD51 homolog 4
It supports RAD51-mediated homologous recombination and chromosome stability after DNA double-strand breaks. Heterozygous loss-of-function variants confer substantial ovarian-cancer risk and a more moderate increase in breast-cancer susceptibility.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RAD51D have source records linked to Gastric cancer. Association strength is not clinical gene validity.
ATM: Serine-protein kinase ATM
It is activated by DNA double-strand breaks and coordinates checkpoint arrest, repair, and apoptosis through phosphorylation of numerous targets. Biallelic loss causes ataxia-telangiectasia, while heterozygous pathogenic variants increase susceptibility to several cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ATM have source records linked to Gastric cancer. Association strength is not clinical gene validity.
BARD1: BRCA1-associated RING domain protein 1
It forms a heterodimer with BRCA1 that supports homologous recombination, DNA-damage signaling, and ubiquitin-dependent regulation at damaged chromatin. Germline loss-of-function variants confer increased breast-cancer susceptibility, particularly for some aggressive subtypes.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BARD1 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
BRIP1: Fanconi anemia group J protein
It unwinds DNA structures and works with BRCA1 and the Fanconi-anemia pathway to repair damaged replication intermediates and interstrand crosslinks. Biallelic loss causes Fanconi anemia group J, while heterozygous loss-of-function variants increase ovarian-cancer risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRIP1 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
CHEK2: Serine/threonine-protein kinase Chk2
It propagates DNA-damage checkpoint signals to proteins controlling cell-cycle arrest, repair, and apoptosis. Germline loss-of-function variants confer moderate cancer susceptibility, especially for breast cancer, while risk estimates depend on the specific allele and family context.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CHEK2 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
DPYD: Dihydropyrimidine dehydrogenase [NADP(+)]
It performs the rate-limiting catabolic step for uracil and thymine and clears most administered fluoropyrimidine drug. Reduced activity can cause dihydropyrimidine dehydrogenase deficiency and markedly increases the risk of severe 5-fluorouracil or capecitabine toxicity.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in DPYD have source records linked to Gastric cancer. Association strength is not clinical gene validity.
MLH1: DNA mismatch repair protein Mlh1
The protein partners with PMS2 to form MutL alpha, a core complex in post-replicative DNA mismatch repair. By helping correct copying errors in DNA, MLH1 protects genome stability, and inherited MLH1 variants are a major cause of Lynch syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MLH1 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
PDCD1: Programmed cell death protein 1
PDCD1 is an inhibitory receptor on activated T cells that binds PD-L1 and PD-L2. Its signaling helps maintain immune tolerance by restraining T-cell activation, making the protein important in autoimmunity and cancer immunotherapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDCD1 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
PMS2: Mismatch repair endonuclease PMS2
Together with MLH1, it provides endonuclease activity needed to complete DNA mismatch repair after replication errors are recognized. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants cause constitutional mismatch-repair deficiency.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PMS2 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
RAD51C: DNA repair protein RAD51 homolog 3
It participates in RAD51-paralog complexes that promote homologous-recombination repair and restart damaged replication forks. Heterozygous loss-of-function variants increase ovarian and breast-cancer risk, while biallelic variants can cause Fanconi anemia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RAD51C have source records linked to Gastric cancer. Association strength is not clinical gene validity.
TUBA1A: Tubulin alpha-1A chain
An alpha-tubulin chain that pairs with beta-tubulin to build microtubules. Microtubules provide tracks for transport and help shape dividing and migrating cells, making TUBA1A especially important for fetal brain development.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TUBA1A have source records linked to Gastric cancer. Association strength is not clinical gene validity.
MSH6: DNA mismatch repair protein Msh6
Together with MSH2, it recognizes single-base mismatches and small insertion-deletion loops during DNA replication and initiates mismatch repair. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants can cause constitutional mismatch-repair deficiency.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MSH6 have source records linked to Gastric cancer. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): IL1RN, ATP6V1A, FAT2 and MCM5.
ClinVar pathogenic and likely pathogenic variants linked to Gastric cancer
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MUTYH R242C | 242 | Pathogenic / likely pathogenic (★★) | |
| MUTYH R242H | 242 | Pathogenic / likely pathogenic (★★) | |
| FGFR2 W290C | 290 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| FGFR2 E565G | 565 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MUTYH W128R | 128 | Pathogenic / likely pathogenic (★★) | |
| MUTYH R179H | 179 | Pathogenic / likely pathogenic (★★) | |
| MUTYH R238W | 238 | Pathogenic / likely pathogenic (★★) | |
| MUTYH V243F | 243 | Pathogenic / likely pathogenic (★★) | |
| MUTYH G273E | 273 | Pathogenic / likely pathogenic (★★) | |
| MUTYH G283E | 283 | Pathogenic / likely pathogenic (★★) | |
| PIK3CA R38H | 38 | PI3K-ABD | Pathogenic / likely pathogenic (★★) |
| TP53 I251L | 251 | DNA binding | Pathogenic / likely pathogenic (★★) |
| MUTYH P402L | 402 | Nudix hydrolase | Pathogenic / likely pathogenic (★★) |
| MUTYH R271W | 271 | Pathogenic / likely pathogenic (★★) | |
| EPCAM M1I | 1 | Pathogenic / likely pathogenic | |
| PALB2 M1K | 1 | Required for its oligomerization and is importan | Pathogenic / likely pathogenic |
| ERBB2 G776S | 776 | Protein kinase | Pathogenic / likely pathogenic |
| MSH6 V80I | 80 | Pathogenic / likely pathogenic | |
| MUTYH Q411R | 411 | Nudix hydrolase | Pathogenic / likely pathogenic |
Which prediction tools work for Gastric cancer
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- ESM1b (LLR): 92 out of 100
- CATVariant: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 86 out of 100
- MutPred: 83 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 83 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 80 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 78 out of 100
- EVE: 72 out of 100
Same protein, different disease
- Familial adenomatous polyposis also has ClinVar records linked to MUTYH variants; they fall mostly in different places as the Gastric cancer variants (27 pathogenic / likely pathogenic).
- FGFR2-related craniosynostosis also has ClinVar records linked to FGFR2 variants; they fall mostly in different places as the Gastric cancer variants (54 pathogenic / likely pathogenic).
- Crouzon disease also has ClinVar records linked to FGFR2 variants; they fall mostly in different places as the Gastric cancer variants (22 pathogenic / likely pathogenic).
- Pfeiffer syndrome also has ClinVar records linked to FGFR2 variants; they fall mostly in different places as the Gastric cancer variants (13 pathogenic / likely pathogenic).
- Apert syndrome also has ClinVar records linked to FGFR2 variants; they fall mostly in different places as the Gastric cancer variants (6 pathogenic / likely pathogenic).
- Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis also has ClinVar records linked to FGFR2 variants; they fall mostly in different places as the Gastric cancer variants (5 pathogenic / likely pathogenic).
- Urinary bladder cancer also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Gastric cancer variants (6 pathogenic / likely pathogenic).
- Lung adenocarcinoma also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Gastric cancer variants (3 pathogenic / likely pathogenic).
- PIK3CA related overgrowth syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Gastric cancer variants (30 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Gastric cancer variants (23 pathogenic / likely pathogenic).
- Megalencephaly-capillary malformation-polymicrogyria syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Gastric cancer variants (22 pathogenic / likely pathogenic).
- Ovarian neoplasm also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Gastric cancer variants (5 pathogenic / likely pathogenic).
- PIK3CA constitutional syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Gastric cancer variants (4 pathogenic / likely pathogenic).
Diseases related to Gastric cancer
- Hereditary breast ovarian cancer syndrome, also linked to ATM, BARD1, BRIP1, CHEK2 and 7 more
- Colorectal cancer, also linked to APC, ATM, CHEK2, ERBB2 and 7 more
- Ovarian cancer, also linked to APC, ATM, BARD1, BRIP1 and 6 more
- Hereditary breast cancer, also linked to ATM, BARD1, BRIP1, CHEK2 and 6 more
- Breast and/or ovarian cancer, also linked to BARD1, BRIP1, CHEK2, MLH1 and 5 more
- Colon carcinoma, also linked to APC, MLH1, MSH6, MUTYH and 2 more
- Gastric neoplasm, also linked to ERBB2, FGFR2, MUTYH, PDCD1 and 2 more
- Lynch syndrome, also linked to CHEK2, EPCAM, MLH1, MSH6 and 1 more
- Urinary bladder cancer, also linked to ATM, ERBB2, KRAS, PIK3CA and 1 more
- Non-small cell lung carcinoma, also linked to ERBB2, KRAS, PDCD1, PIK3CA and 1 more
- Ovarian neoplasm, also linked to BRIP1, ERBB2, PIK3CA and TP53
- Lung cancer, also linked to ERBB2, KRAS, PDCD1 and PIK3CA
Frequently asked questions
Which genes have records linked to Gastric cancer?
This view contains 21 analyzed proteins: MUTYH, FGFR2, ERBB2, EPCAM, PIK3CA and 16 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 19 pathogenic or likely pathogenic variants, 88 variants of uncertain significance and 51 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 191 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center